Opendata, web and dolomites

CODIC

COmmercializing first-in-class dCTPase Inhibitors for treatment of hematological Cancers

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CODIC project word cloud

Explore the words cloud of the CODIC project. It provides you a very rough idea of what is the project "CODIC" about.

profit    nucleoside    screening    enzymatic    cells    compounds    networks    preclinical    science    clinical    treatment    nontransformed    rights    dctpase    selective    agency    therapy    license    tool    viability    plan    investments       nm    pharmacokinetic    analogues    potent    cytidine    degradation    medicinal    prepare    throughput    th1217    attract    inhibitor    chemistry    shows    clinicians    plays    business    start    grant    commercial    oxcia    repair    combination    strategy    medical    inhibitors    ic50    trials    holds    65    direction    model    vitro    patients    gt    agencies    inhibit    synergistically    exclusive    owns    replication    purified    death    explore    sirna    induces    protein    house    assay    impd    revealed    ab    screen    drug    effort    vivo    10    hits    market    dna    validate    secure    mu    anti    ip    cancer    bodies    cell    dividing    rnai    toxicity    company    therapies    perform    commercialization    discuss    erc    genetic    apoptosis    translational    foundation    regulatory   

Project "CODIC" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 94˙738.00
2    OXCIA AB SE (SOLNA) participant 55˙262.00

Map

 Project objective

In our ERC grant GEnetic NEtworks as a tool for anti-CAncer Drug Development we used siRNA screening and genetic networks to identify dCTPase being involved in DNA repair and replication. Further studies revealed that dCTPase plays a role in the degradation of nucleoside analogues used in cancer treatment. We then used an RNAi approach to validate dCTPase as a target to improve nucleoside analogue therapy. The dCTPase protein was purified and we set up an enzymatic high-throughput assay to screen >65,000 compounds, which generated hits that inhibit dCTPase (IC50~1-10μM). Using in house medicinal chemistry we developed TH1217, a low nM potent and selective dCTPase inhibitor with favourable pharmacokinetic properties. TH1217 synergistically induces apoptosis and cell death in combination with cytidine analogue treatment in cancer cells in vitro and in vivo, but shows no increased toxicity in nontransformed dividing cells. Here, we want to explore the commercial potential of the dCTPase inhibitors identified in the ERC grant. In this programme, we will, with the company Oxcia AB, establish the viability of the business programme using technical analysis, develop a business strategy and direction, specifically secure IP, perform market analysis, develop a business plan, manage preclinical development and prepare for clinical trials in collaboration with clinicians and regulatory bodies, IMPD application to Medical Products Agency and identify and discuss with potential commercialization partners and funding agencies to support cost of clinical trials. We have a non-profit foundation that owns our IP rights in an effort to secure long term support for translational science aimed at bringing new therapies to patients. In our planned business model, we start a new company that holds an exclusive license to the IP from the foundation which is used to develop the overall business programme and attract investments.

 Publications

year authors and title journal last update
List of publications.
2016 Sabin Llona-Minguez, Andreas Höglund, Sylvain A. Jacques, Lars Johansson, José Manuel Calderón-Montaño, Magnus Claesson, Olga Loseva, Nicholas C. K. Valerie, Thomas Lundbäck, Javier Piedrafita, Giovanni Maga, Emmanuele Crespan, Laurent Meijer, Estefanía Burgos Morón, Pawel Baranczewski, Ann-Louise Hagbjörk, Richard Svensson, Elisee Wiita, Ingrid Almlöf, Torkild Visnes, Fredrik Jeppsson, Kristmundur Sigmundsson, Annika Jenmalm Jensen, Per Artursson, Ann-Sofie Jemth, Pål Stenmark, Ulrika Warpman Berglund, Martin Scobie, Thomas Helleday
Discovery of the First Potent and Selective Inhibitors of Human dCTP Pyrophosphatase 1
published pages: 1140-1148, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.5b01741
Journal of Medicinal Chemistry 59/3 2019-07-26

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CODIC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CODIC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

GRAPH-IC (2019)

Silicon-Integrated Graphene Photodetectors for Future Photonic Integrated Circuits – Graph-IC

Read More  

AdaptiveResponse (2018)

The evolution of adaptive response mechanisms

Read More  

DEEPTIME (2020)

Probing the history of matter in deep time

Read More